US Patent

US10588913 — Aqueous suspension agent containing glucocorticosteroid nanoparticles

Formulation · Assigned to Activus Pharma Co Ltd · Expires 2036-05-09 · 10y remaining

Vulnerability score 38/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a pharmaceutical composition containing aqueous suspension nanoparticles of a glucocorticosteroid compound for parenteral administrations, including eye drops.

USPTO Abstract

An aqueous suspension containing as an active component a glucocorticosteroid compound is described. The aqueous suspension contains nanoparticles of a glucocorticosteroid compound and a dispersion stabilizer. The nanoparticles have a mean particle diameter of 300 nm or less and a D90 particle diameter of 450 nm or less. The pharmaceutical compositions containing the aqueous suspension are for parenteral administrations, injections, eye drops or ear drops. More specifically the aqueous suspensions containing glucocorticosteroid nanoparticles are used as an eye drop for treating or preventing inflammatory diseases of the eye or an ear drop for treating or preventing inflammatory diseases of the ear.

Drugs covered by this patent

Patent Metadata

Patent number
US10588913
Jurisdiction
US
Classification
Formulation
Expires
2036-05-09
Drug substance claim
No
Drug product claim
Yes
Assignee
Activus Pharma Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.